<DOC>
	<DOCNO>NCT00595101</DOCNO>
	<brief_summary>To investigate dose response , safety efficacy PF-03187207 patient primary open-angle glaucoma ocular hypertension</brief_summary>
	<brief_title>A Phase 2 , Dose Finding Study PF-03187207 Patients With Primary Open Angle Glaucoma Ocular Hypertension .</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<criteria>Man woman least 20 year age Diagnosis primary openangle glaucoma ocular hypertension one eye . Closed/barely open anterior chamber angle history acute angle closure either eye Contraindications latanoprost nitric oxide treatment Known latanoprost nonresponders</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>